Patients undergoing atrial fibrillation (AFib) ablation who were not properly anticoagulated and did not undergo preprocedural transesophageal echocardiogram (TEE) were significantly more likely to ...

Transcatheter tricuspid valve replacement (TTVR) may be a "feasible and effective approach" for treating high-risk patients with severe tricuspid regurgitation (TR) who have limited therapeutic ...

Compared with oral anticoagulant (OAC)-experienced patients, OAC-naïve patients received the same benefit in decreased bleeding risk with asundexian vs. apixaban but they were also less likely to ...

More patients who received the Watchman 2.5 device compared with the Amulet occluder device for left atrial appendage occlusion experienced high-risk device-related thrombi (DRTs), according to a ...

Transcatheter aortic valve implantation (TAVI) was superior to surgical aortic valve replacement (SAVR) in women with severe aortic stenosis (AS), according to results from the RHEIA trial published ...

An early one-time simultaneous measurement of LDL-C, high-sensitivity C-reactive protein (hsCRP) and lipoprotein(a) (Lp[a]) can independently predict long-term cardiovascular risk, according to a ...

A 21-year-old male collegiate football player presents for an annual physical examination with blood pressure (BP) elevated to 147/82 mm Hg. He is counseled on lifestyle modifications, including the ...

People at high risk for recurrent cardiac events following percutaneous coronary intervention (PCI), a procedure to open blocked arteries, experienced significantly better outcomes with clopidogrel ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

"Refocusing and reframing the definition and discussion of coronary artery disease (CAD) from late-stage ischemia and acute coronary events to early detection of coronary artery atheroma and ...

Coronary atherosclerotic phenotypes, including total plaque volume (TPV), noncalcified plaque (NCP), calcified plaque (CP) and percentage atheroma volume (PAV), assessed by artificial ...

AZD0780, a novel, once-daily oral molecule inhibitor, had a robust, dose-dependent effect in lowering LDL-C and a favorable safety profile in patients with hypercholesterolemia already on background ...